Until recently, researchers have puzzled over how the HIV virus adapts to human hosts.
"Much research has focused on how HIV adapts to antiviral drugs - we wanted to investigate how HIV adapts to us, its human host, over time," says lead author Zabrina Brumme from Simon Fraser University.
Advertisement
In a study published in PLOS Genetics, which traces the evolution of HIV in North America, the Brumme lab and colleagues at the BC Centre for Excellence in HIV/AIDS, Harvard University, the New York Blood Center, and The San Francisco Department of Public Health found evidence that the virus is slowly adapting over time to its human hosts. However, this change is so gradual that it is unlikely to have an impact on vaccine design.
"HIV adapts to the immune response in reproducible ways. In theory, this could be bad news for host immunity - and vaccines - if such mutations were to spread in the population " says Brumme. "Just like transmitted drug resistance can compromise treatment success, transmitted immune escape mutations could erode our ability to naturally fight HIV".
![AIDS and Pregnancy]( "AIDS and Pregnancy")
The Acquired immune deficiency syndrome is brought about by the deadly human immunodeficiency virus. In the USA alone an estimate of 120,000 - 160,000 women are HIV- infected.
Researchers characterized HIV sequences from patients dating from 1979, the beginning of the North American HIV epidemic, to the modern day. Data analysis - which required the painstaking recovery of viral RNA from historic specimens - was led by a trio of SFU graduate students.
The team reconstructed the epidemic's ancestral ("founder") HIV sequence and from there they assessed the spread of immune escape mutations in the population.
"Overall, our results show that the virus is adapting very slowly in North America" said Brumme. "In parts of the world harder hit by HIV though, rates of adaptation could be higher."
The study ends with a message of hope. Says Brumme: "We already have the tools to curb HIV in the form of treatment - and, we continue to advance towards a vaccine and a cure. Together, we can stop HIV/AIDS before the virus subverts host immunity through population-level adaptation."
Source: Eurekalert
AIDS and Pregnancy
The Acquired immune deficiency syndrome is brought about by the deadly human immunodeficiency virus. In the USA alone an estimate of 120,000 - 160,000 women are HIV- infected.
Advertisement
Researchers characterized HIV sequences from patients dating from 1979, the beginning of the North American HIV epidemic, to the modern day. Data analysis - which required the painstaking recovery of viral RNA from historic specimens - was led by a trio of SFU graduate students.
The team reconstructed the epidemic's ancestral ("founder") HIV sequence and from there they assessed the spread of immune escape mutations in the population.
"Overall, our results show that the virus is adapting very slowly in North America" said Brumme. "In parts of the world harder hit by HIV though, rates of adaptation could be higher."
The study ends with a message of hope. Says Brumme: "We already have the tools to curb HIV in the form of treatment - and, we continue to advance towards a vaccine and a cure. Together, we can stop HIV/AIDS before the virus subverts host immunity through population-level adaptation."
Source: Eurekalert
AIDS/HIV - Clinical Features
Encyclopedia section of medindia gives general info about HIV Clinical Features
Advertisement
 AIDS/HIV - Prevention And TransmissionEncyclopedia section of medindia explains in brief about the prevention for AIDS/HIV | Advertisement
|
Advertisement
Recommended Readings
Latest AIDS/HIV News
The Phase 1 trial for a preventive HIV vaccine candidate has initiated enrollment in both the United States and South Africa.
In the United States, African American women make up only 26% of female PrEP users, yet they account for 57% of new infections among women.
Scientists have made a groundbreaking discovery in the fight against HIV/AIDS with the successful resolution of the enigmatic immune-evading HIV protein complex.
Tailored quit-smoking programs are designed to address the risks associated with comorbidity in individuals living with HIV.
DNA editing tool CRISPR-Cas13 helps diagnose and signal the presence of HIV antibodies in HIV patients.
